Gerald A Evans

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8405404/publications.pdf

Version: 2024-02-01

72 1,999 20 43
papers citations h-index g-index

73 73 73 3962
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Characterization of Healthcare-Associated and Community-Associated <i>Clostridioides difficile </i> Infections among Adults, Canada, 2015–2019. Emerging Infectious Diseases, 2022, 28, .	4.3	10
2	Phylogenomics reveals viral sources, transmission, and potential superinfection in early-stage COVID-19 patients in Ontario, Canada. Scientific Reports, 2021, 11, 3697.	3.3	12
3	The case for relaxing no-visitor policies in hospitals during the ongoing COVID-19 pandemic. Cmaj, 2021, 193, E135-E137.	2.0	54
4	Estimating the population health burden of Lyme disease in Ontario, Canada: a microsimulation modelling approach. CMAJ Open, 2021, 9, E1005-E1012.	2.4	3
5	Long-Term Sequelae and Health-Related Quality of Life Associated With Lyme Disease: A Systematic Review. Clinical Infectious Diseases, 2020, 71, 440-452.	5 . 8	26
6	COVID-19 and cancer: do we really know what we think we know?. Nature Reviews Clinical Oncology, 2020, 17, 386-388.	27.6	35
7	Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nature Reviews Clinical Oncology, 2020, 17, 268-270.	27.6	333
8	Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016. Antimicrobial Resistance and Infection Control, 2020, 9, 32.	4.1	12
9	Guidance on the use of antiviral agents for the 2019–2020 influenza season. Jammi, 2020, 5, 57-60.	0.5	2
10	2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada. Jammi, 2020, 5, 214-222.	0.5	0
11	The pitfalls of mass hospital health care worker testing forÂCOVID-19. Jammi, 2020, 5, 121-123.	0.5	O
12	Use of antiviral drugs for seasonal influenza: Foundation document for practitioners—Update 2019. Jammi, 2019, 4, 60-82.	0.5	4
13	Estimating direct healthcare costs attributable to laboratoryâ€confirmed Lyme disease in Ontario, Canada: A populationâ€based matched cohort study using health administrative data. Zoonoses and Public Health, 2019, 66, 428-435.	2.2	5
14	A recipe for antimicrobial stewardship success: Using intervention mapping to develop a program to reduce antibiotic overuse in long-term care. Infection Control and Hospital Epidemiology, 2019, 40, 24-31.	1.8	21
15	Human granulocytic anaplasmosis acquired from a blacklegged tick in Ontario. Cmaj, 2018, 190, E363-E366.	2.0	7
16	Guidance on use of antiviral drugs given potential low vaccine effectiveness for the 2017–2018 influenza season. Jammi, 2018, 3, 1-3.	0.5	1
17	Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for <i>Clostridium difficile</i> infection. Jammi, 2018, 3, 71-92.	0.5	9
18	The evolving epidemiology of <i>Clostridium difficile</i> infection in Canadian hospitals during a postepidemic period (2009–2015). Cmaj, 2018, 190, E758-E765.	2.0	47

#	Article	IF	CITATIONS
19	A rare case of pulmonary <i>Mycobacterium szulgai</i> treated with combined drug therapy and bilateral surgical lung resection. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 166-168.	0.5	O
20	Longitudinal Multicenter Analysis of Outcomes After Cessation of Control Measures for Vancomycin-Resistant Enterococci. Infection Control and Hospital Epidemiology, 2017, 38, 24-30.	1.8	13
21	Burden and risk factors for gastrointestinal symptom distress in HIV patients in the modern antiretroviral era. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 156-167.	1.2	6
22	Sexual behaviors among women living with HIV in Ontario, Canada. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 587-592.	1.2	6
23	AÂLongitudinal Four-year Pre-Post Intervention Study Evaluating the Use of an Antimicrobial Stewardship Application. Open Forum Infectious Diseases, 2017, 4, S260-S260.	0.9	0
24	Adequacy of Mental Health Services for HIV-Positive Patients with Depression: Ontario HIV Treatment Network Cohort Study. PLoS ONE, 2016, 11, e0156652.	2.5	16
25	Assessing the magnitude and trends in hospital acquired infections in Canadian hospitals through sequential point prevalence surveys. Antimicrobial Resistance and Infection Control, 2016, 5, 19.	4.1	17
26	Comparison of coping strategies and supports between aboriginal and non-aboriginal people living with HIV in Ontario. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 63-69.	1,2	3
27	Update on influenza antiviral drug treatment and prophylaxis for the 2015–2016 influenza season. Jammi, 2016, 1, 1-4.	0.5	0
28	Guidance on The Use of Antiviral Drugs for Influenza in Acute Care Facilities in Canada, 2014-2015. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, e5-e8.	1.9	4
29	Guidance for Practitioners on the Use of Antiviral Drugs to Control Influenza Outbreaks in Long-Term Care Facilities in Canada, 2014-2015 Season. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, e1-e4.	1.9	7
30	The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases. Medical Decision Making, 2015, 35, 145-147.	2.4	0
31	Lyme disease: How reliable are serologic results?. Cmaj, 2015, 187, 1193-1194.	2.0	5
32	High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada. BMC Infectious Diseases, 2015, 15, 356.	2.9	56
33	Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole. PLoS ONE, 2014, 9, e82622.	2.5	72
34	A confusing Case –Weissella confusaProsthetic Joint Infection: A Case Report and Review of the Literature. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 173-175.	1.9	21
35	Renal Failure, Hepatitis and Myocarditis in A Previously Healthy Man. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 133-134.	1.9	1
36	Microbial source tracking and spatial analysis of E. coli contaminated private well waters in southeastern Ontario. Journal of Water and Health, 2014, 12, 348-357.	2.6	17

#	Article	IF	Citations
37	Toward a Functional Definition of a "Rare Disease―for Regulatory Authorities and Funding Agencies. Value in Health, 2014, 17, 757-761.	0.3	21
38	Opportunity Cost of Funding Drugs for Rare Diseases. Medical Decision Making, 2014, 34, 1016-1029.	2.4	53
39	Application of a Policy Framework for the Public Funding of Drugs for Rare Diseases. Journal of General Internal Medicine, 2014, 29, 774-779.	2.6	18
40	The Vioxx® legacy: Enduring lessons from the not so distant past. Cardiology Journal, 2014, 21, 203-205.	1.2	9
41	The Velvet Myocardium: Potential Harbinger of Death in Acute Myocarditis?. Canadian Journal of Cardiology, 2013, 29, 1742.e25-1742.e27.	1.7	1
42	Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. Journal of Antimicrobial Chemotherapy, 2013, 68, 1505-1509.	3.0	51
43	A spatial analysis of private well water Escherichia coli contamination in southern Ontario. Geospatial Health, 2013, 8, 65.	0.8	16
44	The Use of Antiviral Drugs for Influenza: A Foundation Document for Practitioners. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 1C-15C.	1.9	8
45	Emergency Department Surveillance as a Proxy For The Prediction of Circulating Respiratory Viral Disease in Eastern Ontario. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 150-154.	1.9	16
46	Application of Operations Research to Funding Decisions for Treatments with Rare Disease. Profiles in Operations Research, 2013, , 281-294.	0.4	2
47	An Evaluation Framework for Funding Drugs for Rare Diseases. Value in Health, 2012, 15, 982-986.	0.3	40
48	AMMI Canada Position Paper: 2012 Mandatory Influenza Immunization of Health Care Workers. Canadian Journal of Infectious Diseases and Medical Microbiology, 2012, 23, e93-e95.	1.9	10
49	The Use of Antiviral Drugs for Influenza: Guidance for Practitioners 2012/2013. Canadian Journal of Infectious Diseases and Medical Microbiology, 2012, 23, e79-e92.	1.9	27
50	Acute orbital inflammatory syndrome following H1N1 immunization. Canadian Journal of Ophthalmology, 2011, 46, 552-553.	0.7	13
51	Canadian clinical practice guidelines for acute and chronic rhinosinusitis. Allergy, Asthma and Clinical Immunology, 2011, 7, 2.	2.0	153
52	Canadian clinical practice guidelines for acute and chronic rhinosinusitis. Executive summary. Journal of Otolaryngology - Head and Neck Surgery, 2011, 40 Suppl 2, S91-8.	1.9	1
53	Canadian Practice Guidelines for Surgical Intra-Abdominal Infections. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, 11-37.	1.9	40
54	Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, e122-e150.	1.9	56

#	Article	IF	CITATIONS
55	Health technology assessment: A comprehensive framework for evidence-based recommendations in Ontario. International Journal of Technology Assessment in Health Care, 2009, 25, 141-150.	0.5	60
56	Clinical Practice Guidelines for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 19-53.	1.9	203
57	RETIRED: Canadian Consensus Guidelines on Human Papillomavirus. Journal of Obstetrics and Gynaecology Canada, 2007, 29, S1.	0.7	18
58	Impact of a Fluoroquinolone Restriction Policy in an Elderly Population. American Journal of Medicine, 2007, 120, 893-900.	1.5	39
59	Laboratory diagnosis of human infection with avian influenza. Cmaj, 2006, 175, 1371-1371.	2.0	1
60	Complicated Urinary Tract Infection in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2005, 16, 349-360.	1.9	186
61	The Management of Infection and Colonization due to Methicillin-ResistantStaphylococcus aureus: A CIDS/CAMM Position Paper. Canadian Journal of Infectious Diseases & Medical Microbiology, 2004, 15, 39-48.	0.3	26
62	Recurrent Chronic Ambulatory Peritoneal Dialysis-Associated Infection due to <i>Rothia dentocariosa</i> . Canadian Journal of Infectious Diseases and Medical Microbiology, 2004, 15, 171-173.	1.9	15
63	HYPERSENSITIVITY REACTION ASSOCIATED WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR INTERSTITIAL CYSTITIS. Journal of Urology, 2004, 172, 537-537.	0.4	6
64	Infection Control for the Otolaryngologist in the Era of Severe Acute Respiratory Syndrome. The Journal of Otolaryngology, 2003, 32, 281.	0.6	4
65	The oxazolidinones. Current Infectious Disease Reports, 2002, 4, 17-27.	3.0	11
66	Macrolides: A Canadian Infectious Disease Society Position Paper. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 218-231.	0.3	13
67	Antimicrobial Regimens Prescribed by Canadian Physicians for Chemotherapy-Induced Febrile Neutropenic Episodes. Canadian Journal of Infectious Diseases & Medical Microbiology, 1999, 10, 353-357.	0.3	2
68	Oral histoplasmosis masquerading as an invasive carcinoma. Journal of Oral and Maxillofacial Surgery, 1995, 53, 1110-1114.	1.2	15
69	Growth of Coagulase Negative Staphylococci in Peritoneal Dialysate Fluid. ASAIO Journal, 1994, 40, M431-M434.	1.6	7
70	Clostridium sordellii infection and toxin neutralization. Pediatric Infectious Disease Journal, 1990, 9, 582-585.	2.0	7
71	Mutation of Host Cell Determinants which Discriminate between Lytic and Persistent Mouse Hepatitis Virus Infection Results in a Fusion-resistant Phenotype. Journal of General Virology, 1989, 70, 3335-3346.	2.9	12
72	Factitious AIDS. New England Journal of Medicine, 1988, 319, 1605-1606.	27.0	13